TMSB10 and prostate cancer: In prostate cancer cohorts using overall survival (OS) as an endpoint, high TMSB10 expression was associated with a trend toward poorer prognosis in GSE16560, ICGC, and TCGA cohorts (Figure 2A), though limited by small sample sizes and the slow progression of prostate cancer.